Terms: = Gastric cancer AND VHL, HRCA1, P40337, 7428, ENSG00000134086, RCA1, VHL1 AND Treatment
9 results:
1. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer.
Wei Y; Zhang L; Wang C; Li Z; Luo M; Xie G; Yang X; Li M; Ren S; Zhao D; Gao R; Gong JN
Animal Model Exp Med; 2023 Jun; 6(3):245-254. PubMed ID: 37271936
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting vhl for the treatment of gastric cancer.
Wang XR; Wang S; Mu HX; Xu KY; Wang XT; Shi JT; Cui QH; Zhang LW; Chen SW
Eur J Med Chem; 2022 Dec; 244():114821. PubMed ID: 36242985
[TBL] [Abstract] [Full Text] [Related]
3. Comparative analysis of cancer gene mutations using targeted sequencing in matched primary and recurrent gastric cancers after chemotherapy.
Huh YJ; Cho SY; Cho MS; Lee KE; Lee JH
Genes Genomics; 2022 Nov; 44(11):1425-1435. PubMed ID: 35622232
[TBL] [Abstract] [Full Text] [Related]
4. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis.
Ito T; Masui T; Komoto I; Doi R; Osamura RY; Sakurai A; Ikeda M; Takano K; Igarashi H; Shimatsu A; Nakamura K; Nakamoto Y; Hijioka S; Morita K; Ishikawa Y; Ohike N; Kasajima A; Kushima R; Kojima M; Sasano H; Hirano S; Mizuno N; Aoki T; Aoki T; Ohtsuka T; Okumura T; Kimura Y; Kudo A; Konishi T; Matsumoto I; Kobayashi N; Fujimori N; Honma Y; Morizane C; Uchino S; Horiuchi K; Yamasaki M; Matsubayashi J; Sato Y; Sekiguchi M; Abe S; Okusaka T; Kida M; Kimura W; Tanaka M; Majima Y; Jensen RT; Hirata K; Imamura M; Uemoto S
J Gastroenterol; 2021 Nov; 56(11):1033-1044. PubMed ID: 34586495
[TBL] [Abstract] [Full Text] [Related]
5. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract] [Full Text] [Related]
6. Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.
de Haas S; Delmar P; Bansal AT; Moisse M; Miles DW; Leighl N; Escudier B; Van Cutsem E; Carmeliet P; Scherer SJ; Pallaud C; Lambrechts D
Angiogenesis; 2014 Oct; 17(4):909-20. PubMed ID: 25012543
[TBL] [Abstract] [Full Text] [Related]
7. Management of endolymphatic sac tumors: sporadic cases and von Hippel-Lindau disease.
Nevoux J; Nowak C; Vellin JF; Lepajolec C; Sterkers O; Richard S; Bobin S
Otol Neurotol; 2014 Jun; 35(5):899-904. PubMed ID: 24662627
[TBL] [Abstract] [Full Text] [Related]
8. Inhibition of endothelial cell proliferation by targeting Rac1 GTPase with small interference RNA in tumor cells.
Xue Y; Bi F; Zhang X; Pan Y; Liu N; Zheng Y; Fan D
Biochem Biophys Res Commun; 2004 Aug; 320(4):1309-1315. PubMed ID: 15303276
[TBL] [Abstract] [Full Text] [Related]
9. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas.
van Dekken H; Geelen E; Dinjens WN; Wijnhoven BP; Tilanus HW; Tanke HJ; Rosenberg C
Cancer Res; 1999 Feb; 59(3):748-52. PubMed ID: 9973227
[TBL] [Abstract] [Full Text] [Related]
